Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03864978
Other study ID # REROS/001/17
Secondary ID 2017-003722-33
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 22, 2018
Est. completion date October 2020

Study information

Verified date March 2019
Source Alfasigma S.p.A.
Contact Alessandro Blè, MD
Phone +39-051-6489619
Email alessandro.ble@alfasigma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Preliminary evidence suggests that treatment with rifaximin may be beneficial in patients with papulopustular rosacea.

The present clinical trial is aimed to investigate the safety and efficacy of oral rifaximin delayed release versus placebo in adults with moderate-to-severe papulopustular rosacea (a.k.a. subtype II) and positive lactulose H2/CH4 breath test.


Recruitment information / eligibility

Status Recruiting
Enrollment 236
Est. completion date October 2020
Est. primary completion date April 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Key inclusion Criteria:

1. Men and women aged 18 to 70 years at screening.

2. Female participants are eligible if they are either of non-childbearing potential or of childbearing potential with a negative pregnancy test result at screening and randomization and agreeing to use a highly effective method of contraception until 72 hours after taking the last study treatment dose.

3. Moderate-to-severe papulopustular rosacea (a.k.a. subtype II, RII) at screening and confirmed at randomization. Moderate-to-severe rosacea is defined as the presence of 11 or more facial papules or pustules with or without plaques.

4. Positivity of lactulose H2/CH4 breath test (L-BT) within the last 2-weeks before randomization.

5. Patients accepting to provide and legally capable of providing free and informed consent to all procedures included in the protocol (including facial skin photography).

Key exclusion Criteria:

1. Granulomatous rosacea or rosacea fulminans.

2. Erythematoteleangectatic, phymatous or ocular rosacea only. Patients with these subtypes associated with papulopustular rosacea can be enrolled.

3. Circulating anti-helicobacter pylori IgM and/or IgG at screening (V1).

4. Positivity at the faecal Clostridium Difficile toxin assay at screening (V1).

5. History or family history of inflammatory bowel disease (Crohn's disease or ulcerative colitis) or other conditions characterized by severe intestinal ulcers.

6. History or family history of coeliac disease.

7. Patients with intestinal obstruction or partial intestinal obstruction.

8. Presence of diarrhoea associated with fever and/or blood in the stool.

9. Health conditions requiring continuous or intermittent treatment with facial topical, inhaled or systemic steroids and/or biologic or non-biologic immunosuppressive or immunomodulatory agents (e.g. autoimmune diseases, etc.).

10. Severe kidney impairment (i.e. estimated glomerular filtration rate <30 ml/min).

11. Severe hepatic impairment (i.e. Child-Pugh B or C).

12. Cancer or any cancer-related treatment within 5 years prior to screening (excluding non-melanoma skin-cancer).

13. History of alcohol or drug abuse within a year prior to screening.

14. Facial skin conditions that can interfere with reliable assessment of rosacea throughout the study (e.g. keloids, hypertrophic scarring, recent facial surgery etc.)

15. Any other significant health condition (e.g. cardiovascular, respiratory, renal, hepatic, neurologic, psychiatric, hematologic, oncologic, immune etc.) that in the investigator's judgement may: i) jeopardize the patient's safe participation in the trial or ii) make unlikely the patient's completion of the study or iii) make unlikely the patient's compliance with the study procedures (e.g. highly anticipated need of non-permitted treatments, terminal illness, etc.).

16. History of hypersensitivity to rifaximin, rifamycin-derivatives, any of the rifaximin-EIR excipients, or any UV protection cream component.

17. Treatment with biologic immunomodulatory and/or immunosuppressive drugs (e.g. anti-TNF drugs) within 6 months prior to randomization.

18. Treatment with non-biologic immunomodulatory and/or immunosuppressive drugs (e.g. cyclosporine, methotrexate etc.) within 30 days prior to randomization.

19. Treatment with warfarin within 14 days prior to randomization.

20. Treatment with niacin within 30 days prior to randomization.

21. Topical facial or systemic antibiotics within 30 days before randomization;

22. Treatment with neomycin or other low-absorbable oral antibiotics (such as marketed rifaximin) within 90 days before randomization.

23. Topical facial, inhaled or systemic corticosteroids within 30 days prior to randomization.

24. Topical facial retinoids within 30 days before randomization.

25. Systemic retinoids within 6 months before randomization.

26. Any other topical or systemic treatment for rosacea within 30 days before randomization (including also laser and pulsed light, etc.).

27. Pharmaceutical prebiotics and probiotics (functional food is allowed), within 30 days before randomization.

28. Any experimental treatment within 6 months prior to randomization.

29. Women who are pregnant, breast-feeding or planning a pregnancy during the trial period.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rifaximin delayed release 400 mg tablet
Rifaximin delayed release
Placebo
Placebo

Locations

Country Name City State
Italy Ospedali Riuniti di Ancona Ancona
Italy Policlinico di Bari Bari
Italy Policlinico Sant'Orsola Malpighi Bologna
Italy Spedali Civili Brescia
Italy Policlinico Vittorio Emanuele Catania
Italy Ospedale Policlinico San Martino Genova
Italy Ospedale della Misericordia Grosseto
Italy Policlinico di Modena Modena
Italy Azienda Ospedaliera Universitaria Federico II Napoli
Italy Policlinico Universitario A. Gemelli Roma
Italy Azienda Ospedaliera Santa Maria Terni
Italy A.O.U. Città della Salute e della Scienza Torino

Sponsors (1)

Lead Sponsor Collaborator
Alfasigma S.p.A.

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Other Mean change from Baseline (day 1) in circulating inflammatory marker levels at 10 ± 1, day 30 ± 1 and day 60 ± 3 change respect to baseline 10, 30 and 60 days
Other Mean change from baseline (day 1) skin texture index at 10 ± 1, day 30 ± 1 and day 60 ± 3 as provided by Canfield Image Analysis change respect to baseline 10, 30 and 60 days
Primary Mean change from baseline (day 1) in number of rosacea inflammatory lesions (papules, pustules or plaques) at the end of treatment visit (day 30 ± 1) changes in number of lesions 30 days
Primary Percent of participants showing treatment success (IGA score of 0 [clear] or 1 [almost clear]) at the end of treatment visit (day 30 ± 1) per cent changes in IGA score 0 and 1 patients 30 days
Secondary Mean change from Baseline (day 1) in number of rosacea inflammatory lesions at the end of treatment visit (day 30 ± 1) as provided by Canfield Image Analysis changes respect to baseline 30 days
Secondary Mean change from Baseline (day 1) in number of inflammatory lesions (papules, pustules or plaques) at day 10 ± 1 and day 60 ± 3 change respect to baseline 10 and 60 days
Secondary Percent of participants showing treatment success (i.e. IGA score of 0 or 1) at day 10 ± 1 and day 60 ± 3 per cent changes in IGA score 0 and 1 patients 10 and 60 days
Secondary Percent of participants with IGA score of 0 (clear) at day 10 ± 1, day 30 ± 1 and day 60 ± 3 per cent changes in IGA score 0 patients 10, 30 and 60 days
Secondary Mean change from Baseline (day 1) in the following rosacea additional features at day 10 ± 1, day 30 ± 1 and day 60 ± 3: • burning or stinging • telangiectasia • ocular manifestations • phymatous changes change respect to baseline 10, 30 and 60 days
Secondary Mean change from Baseline (day 1) in facial non-transient erythema at day 10 ± 1, day 30 ± 1 and day 60 ± 3 (absent=0, mild=1, moderate=2, severe=3) change respect to baseline 10, 30 and 60 days
Secondary Mean change from Baseline (day 1) in number of inflammatory lesions at day 10 ± 1 and day 60 ± 3 as provided by Canfield Image Analysis change respect to baseline 10 and 60 days
Secondary Mean change from Baseline (day 1) in facial non-transient erythema score at day 10 ± 1, day 30 ± 1 and day 60 ± 3, based on global fractional area redness as provided by Canfield Image Analysis change respect to baseline 10, 30 and 60 days
Secondary Mean change from Baseline in Basic Self-Esteem Scale at day 30 ± 1 and day 60 ± 3 change respect to previous evaluation 30 and 60 days
Secondary Mean change from Baseline (day 1) in Dermatology Life Quality Index (10-item DLQI) at day 30 ± 1 and day 60 ± 3 change respect to baseline 30 and 60 days
Secondary Mean difference in Treatment Satisfaction Questionnaire between study groups at day 30 ± 1 differences between treatment arms 30 days
See also
  Status Clinical Trial Phase
Completed NCT03276936 - A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea Phase 3
Completed NCT02601963 - Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea Phase 2
Completed NCT02268474 - Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea N/A
Completed NCT01555463 - Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea Phase 3
Active, not recruiting NCT03667222 - Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea Phase 2
Terminated NCT03564145 - A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea Phase 3
Completed NCT05150587 - Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea Phase 2
Completed NCT03263273 - Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea Phase 2
Completed NCT05343455 - A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2) Phase 3
Completed NCT01784133 - A Twelve Week Safety and Efficacy Study in Rosacea Phase 2
Completed NCT01872715 - Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea Phase 4
Completed NCT05296629 - A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea. Phase 3
Completed NCT05838170 - Study of TP-04 in Participants With Papulopustular Rosacea Phase 2
Recruiting NCT06013371 - PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea Phase 2
Completed NCT03564119 - A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea Phase 3
Completed NCT03079531 - Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea Phase 1/Phase 2
Completed NCT01045551 - Open Label Pilot Study of Apremilast in Treatment of Rosacea Phase 2
Completed NCT03448939 - A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea Phase 3
Completed NCT05675501 - Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties Phase 1
Withdrawn NCT03883945 - A Safety and Efficacy Study to Evaluate Rosacea Phase 1/Phase 2